Pharmaceutical Market India, Switzerland and Spain Report At Researchmoz.us

Researchmoz presents this most up-to-date research on"Market Research On Pharmaceutical Market India, Switzerland and Spain Report At Researchmoz.us". The report focuses primarily on quantitative market metrics in order to characterize the growth and evolution of the Remote Patient Monitoring Market.

The Pharmaceutical Market: India http://www.researchmoz.us/the-pharmaceutical-market-india-report.html

The outlook for India's patented drug market is not promising. The primary reason why sales of these products will not grow swiftly is the country's intellectual property (IP) regime, which is well below international standards. It does not recognise incremental improvements and as such few medicines receive exclusivity. The outlook is also restricted by the government's apparent desire to spend as little as possible on medical services. Whileprudenceis virtuous in an indebted global economy, India still needs to spend the 'market rate' for healthcare infrastructure, doctors, nurses, medical devices and innovative pharmaceuticals. Without the necessary therapeutics, healthcare rofessionals, hospitals andclinics, India's healthcare indicators will not improve as desired by the authoritiesand, more importantly,bypatients and their families.

Borwse More Reports On Pharmaceutical At : http://www.researchmoz.us/pharmaceutical-market-reports-38.html

Headline Expenditure Projections

• Pharmaceuticals: INR730.0bn (US$15.6bn) in 2011 to INR839.4bn (US$15.7bn) in 2012; +15.0% in local currency terms and +0.3% in US dollar terms. Our US dollar forecast is significantly lower than in Q312 due to weakening of the rupee.
• Healthcare: INR3,353.7bn (US$71.9bn) in 2011 to INR3,746.3bn (US$70.0bn) in 2012; +11.7% in local currency terms and -2.6% in US dollar terms. Our US dollar forecast is significantly lower than in Q312 due to weakening of the rupee.
• Medical devices: INR138.9bn (US$3.0bn) in 2011 to INR153.3bn (US$2.9bn) in 2012; +10.4% in local currency terms and -3.7% in US dollar terms. Our US dollar forecast is significantly lower than in Q312 due to weakening of the rupee.

The Pharmaceutical Market: Switzerland http://www.researchmoz.us/the-pharmaceutical-market-switzerland-report.html

While the patent cliff and the consequent availability of generic drugs, as well as price cuts on generic medicines and their increasing affordability, will work towards increasing the consumption of generic medicines in Switzerland, BMI believes the government needs to do more to alter patients' attitudes towards these drugs as this the main deterrent of growth.Headline Expenditure Projections

Pharmaceuticals: CHF6.77bn (US$7.63bn) in 2011 to CHF6.58bn (US$7.00bn) in 2012; -2.8% decline in local currency terms and -8.2% in US dollar terms.
Healthcare: CHF65.30bn (US$73.6bn) in 2011 to CHF67.42bn (US$71.72bn) in 2012; +3.2% growth in local currency terms and -2.6% in US dollar terms.
Medical devices: CHF4.77bn (US$5.38bn) in 2011 to CHF4.76bn (US$5.06bn) in 2012; -0.3% growth in local currency term s and -5.8% in US dollar terms.

The Pharmaceutical Market: Spain http://www.researchmoz.us/the-pharmaceutical-market-spain-report.html

The sharp drop in public pharmaceutical expenditure in Spain in the first four months of 2012 serves as a warning for the continuation of a fall in spending on medicines in the remainder of the year. BMI notes that this does not bode well for drugmakers selling their products in Spain as the success of the implemented policies may encourage the enforcement of further cost-containment measures, which, together with the ongoing public hospital debt situation, seriously hampers the country's attractiveness as a location in which to sell drugs, despite its favourable demographic characteristics.

Headline Expenditure Projections

Pharmaceuticals: EUR20.15bn (US$28.00bn) in 2011 to EUR18.34bn (US$23.30bn) in 2012; -9.0% in local currency terms and -16.8% in US dollar terms.
Healthcare: EUR104.99bn (US$145.93bn) in 2011 to EUR105.51bn (US$133.99bn) in 2012; +0.5% in local currency terms and -8.2% in US dollar terms.
Medical Devices: EUR4.32bn (US$6.01bn) in 2011 to EUR4.35bn (US$5.52bn) in 2011; +0.7% in local currency terms and -8.0% in US dollar terms.

For More Information Kindly Contact:
Email: sales@researchmoz.us
Web Site: http://www.researchmoz.us/
word press : http://marketresearchtopix.wordpress.com